PFIZER REPORTS FIRST-QUARTER 2017 RESULTS

NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) reported financial results for first-quarter 2017
and reaffirmed its 2017 financial guidance.

On June 24, 2016, Pfizer acquired Anacor Pharmaceuticals, Inc. (Anacor).
Therefore, financial results for first-quarter 2017 reflect three months
of legacy Anacor operations, which were immaterial.

On September 28, 2016, Pfizer acquired Medivation, Inc. (Medivation).
Therefore, financial results for first-quarter 2017 reflect three months
of legacy Medivation operations.

On February 3, 2017, Pfizer completed the sale of its global infusion
therapy net assets, Hospira Infusion Systems (HIS). Therefore, financial
results for first-quarter 2017 reflect approximately one month of legacy
HIS domestic operations and approximately two months of legacy HIS
international operations, while financial results for first-quarter 2016
reflect three months of legacy HIS global operations.⁽³⁾

Some amounts in this press release may not add due to rounding. All
percentages have been calculated using unrounded amounts. References to
operational variances pertain to period-over-period growth rates that
exclude the impact of foreign exchange.⁽⁴⁾ Results for the
first quarter of 2017 and 2016 are summarized below.

2017 FINANCIAL GUIDANCE⁽⁵⁾

CAPITAL ALLOCATION

• During first-quarter 2017, Pfizer returned $6.9 billion directly to
  shareholders, through a combination of:
  • a $1.9 billion dividend payment, or $0.32 per share of common
    stock; and
  • a $5.0 billion accelerated share repurchase agreement executed in
    February 2017.
• As of May 2, 2017, Pfizer’s remaining share repurchase authorization
  was approximately $6.4 billion.

EXECUTIVE COMMENTARY

Ian Read, Chairman and Chief Executive Officer, stated, “I was pleased
with our first-quarter 2017 financial performance, which was in line
with our expectations, and it reinforces our confidence in the business
going forward. I believe each of our businesses is well positioned
within their individual markets with strong portfolios, highly skilled
and accomplished leadership and focused strategies. Innovative Health’s
core franchises — Prevnar 13, Lyrica, Ibrance, Eliquis, Xeljanz and
Xtandi — have strong leadership positions in their respective
therapeutic categories and are complemented by new product launches,
including Eucrisa and Bavencio, as well as meaningful pipeline progress.
Essential Health’s growth opportunities — Sterile Injectables,
Biosimilars and Emerging Markets — continue to perform in line with our
expectations while we refine the business and position it for potential
sustainable revenue growth.

“Finally, we will continue to allocate our capital to initiatives that
we believe will maximize value creation,” Mr. Read concluded.

Frank D’Amelio, Executive Vice President, Business Operations and Chief
Financial Officer, stated, “Today we are reaffirming our 2017 financial
guidance, reflecting our performance to date as well as our confidence
in the business going forward. Excluding the negative impacts of the
divestiture of HIS and foreign exchange, the midpoints of our 2017
revenue and Adjusted diluted EPS⁽²⁾ guidance ranges reflect
4% and 10% operational growth, respectively.”

QUARTERLY FINANCIAL HIGHLIGHTS (First-Quarter 2017 vs. First-Quarter
2016)

First-quarter 2017 revenues totaled $12.8 billion, a decline of $226
million, or 2% compared to the prior-year quarter, reflecting an
operational decline of $110 million, or 1%, and the unfavorable impact
of foreign exchange of $116 million, or 1%.

Excluding the revenues for HIS in both periods and the unfavorable
impact of foreign exchange, first-quarter 2017 revenues increased by $97
million, or 1%. First-quarter 2017 revenues excluding the net impact of
acquisitions and divestitures completed in 2016 and 2017 were flat
operationally compared to first-quarter 2016.

Of note, there was one less selling day in the U.S. and two fewer
selling days in international markets during first-quarter 2017 compared
to first-quarter 2016, resulting in a negative impact on first-quarter
2017 revenues of approximately $300 million compared to the prior-year
quarter. Full-year 2017 will have one less U.S. selling day and one less
international selling day compared to full-year 2016.

Innovative Health Highlights

• IH revenues increased 6% operationally in first-quarter 2017, driven
  by continued growth from key brands including Ibrance and Eliquis
  globally, the addition of Xtandi revenues in the U.S. resulting from
  the September 2016 acquisition of Medivation, as well as Lyrica and
  Xeljanz, both primarily in the U.S. Global Ibrance revenue increased
  59% operationally while global operational revenue growth for Eliquis
  and Xeljanz was 52% and 27%, respectively.
• Global Prevnar 13/Prevenar 13 revenues declined 7% operationally. In
  the U.S., Prevnar 13 revenues decreased 9% primarily due to the
  continued decline in revenues for the Adult indication due to a
  smaller remaining “catch up” opportunity compared to the prior-year
  quarter, partially offset by the favorable impact from the timing of
  government purchases for the pediatric indication. Prevenar 13
  revenues in international markets decreased 4% operationally,
  primarily due to the unfavorable timing of government purchases in
  certain emerging markets for the pediatric indication, partially
  offset by modest growth of the Adult indication in certain developed
  Europe markets.
• First-quarter 2017 operational growth was also negatively impacted by
  lower revenues for Enbrel in most developed Europe markets, primarily
  due to continued biosimilar competition, as well as by Viagra in the
  U.S. primarily due to lower market demand.

Essential Health Highlights

• First-quarter 2017 EH revenues declined 9% operationally, primarily
  resulting from a 23% operational decline from Peri-LOE Products,
  including Pristiq in the U.S., which lost marketing exclusivity in the
  U.S. in March 2017, Lyrica in most developed Europe markets and Zyvox
  in developed Europe and in the U.S., a 68% decline in HIS revenues,
  reflecting its February 3, 2017 divestiture, and a 5% operational
  decline from Legacy Established Products (LEP). These declines were
  partially offset by 3% operational growth from the Sterile Injectable
  Pharmaceuticals (SIP) portfolio and 62% operational growth from
  Biosimilars, primarily driven by Inflectra in certain developed Europe
  markets and in the U.S. EH revenues excluding the performance of HIS
  in both periods declined 6% operationally.
• Developed markets revenues declined 14% operationally, negatively
  impacted by a 34% operational decline from Peri-LOE Products, a 72%
  operational decline in HIS revenues and a 9% operational decline from
  the LEP portfolio, partially offset by 62% operational growth from
  Biosimilars. Excluding the performance of HIS in both periods, EH
  revenues in developed markets declined 10% operationally.
• Revenues in emerging markets grew 5% operationally, primarily driven
  by 21% operational growth from the SIP portfolio. Excluding the
  performance of HIS in both periods, EH revenues in emerging markets
  grew 6% operationally.

GAAP Reported⁽¹⁾ Income Statement Highlights

Adjusted⁽²⁾ Income Statement Highlights

The diluted weighted-average shares outstanding used to calculate
Reported⁽¹⁾ and Adjusted⁽²⁾ diluted EPS declined
by 133 million shares compared to the prior-year quarter due to Pfizer’s
share repurchase program, reflecting the impact of a $5 billion
accelerated share repurchase agreement executed in March 2016 and
completed in June 2016 and another $5 billion accelerated share
repurchase agreement executed in February 2017.

A full reconciliation of Reported⁽¹⁾ to Adjusted⁽²⁾
financial measures and associated footnotes can be found starting on
page 18 of the press release located at the hyperlink below.

RECENT NOTABLE DEVELOPMENTS (Since January 31, 2017)

Product Developments

• Bavencio (avelumab)
  • In March 2017, EMD Serono Inc. (EMD Serono), the biopharmaceutical
    business of Merck KGaA, Darmstadt, Germany, in the U.S. and
    Canada, and Pfizer announced that the U.S. Food and Drug
    Administration (FDA) approved Bavencio Injection 20 mg/mL, for
    intravenous use, for the treatment of adults and pediatric
    patients 12 years and older with metastatic Merkel cell carcinoma
    (mMCC). This indication is approved under accelerated approval
    based on tumor response and duration of response. Continued
    approval for this indication may be contingent upon verification
    and description of clinical benefit in confirmatory trials.
    Bavencio, a human anti-PD-L1 antibody, is the first FDA-approved
    therapy for patients with mMCC, a rare and aggressive skin cancer.
  • In February 2017, EMD Serono and Pfizer announced that the FDA
    accepted for Priority Review EMD Serono’s Biologics License
    Application (BLA) for avelumab as a treatment for patients with
    locally advanced or metastatic urothelial carcinoma with disease
    progression on or after platinum-based therapy. The FDA has set a
    Prescription Drug User Fee Act (PDUFA) target action date of
    August 27, 2017 for avelumab in this indication.
• Eliquis (apixaban) — In March 2017, Bristol-Myers Squibb
  Company and Pfizer announced findings from a real-world data analysis
  of the U.S. Medicare database comparing the risk of stroke or systemic
  embolism and rate of major bleeding among patients with non-valvular
  atrial fibrillation who were treated with direct oral anticoagulants
  versus warfarin. In the analysis, titled Effectiveness and Safety
  of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin among
  Non-Valvular Atrial Fibrillation Patients in the U.S. Medicare
  Population, Eliquis was associated with a significantly lower risk
  of stroke or systemic embolism and lower rate of major bleeding
  compared to warfarin. These data, which supplement results from
  randomized trials, were presented at the American College of
  Cardiology’s 66^th Annual Scientific Session.
• Ibrance (palbociclib) — In March 2017, Pfizer announced that
  the FDA approved a supplemental New Drug Application for Ibrance,
  based on the results from the confirmatory Phase 3 trial, PALOMA-2.
  The FDA action converts the accelerated approval of Ibrance to regular
  approval and broadens the range of anti-hormonal therapy that may be
  administered with Ibrance. Ibrance now is indicated in combination
  with an aromatase inhibitor, expanding on its earlier indication in
  combination with letrozole, as initial endocrine based therapy for
  postmenopausal women with hormone receptor-positive, human epidermal
  growth factor receptor 2-negative advanced or metastatic breast cancer.
• Inflectra (infliximab-dyyb) — In February 2017, Pfizer and
  Celltrion Healthcare announced that data presented at the 12^th
  Congress of the European Crohn’s and Colitis Organisation showed that
  for patients with moderate-to-severe Crohn’s disease (CD), treatment
  with Inflectra has similar efficacy and safety to treatment with
  Remicade^®(6), its reference product. The randomized 54-week
  clinical trial in 214 patients met its primary endpoint demonstrating
  that, at six weeks, Inflectra was similar to Remicade^®(6)
  in the treatment of CD thereby meeting the criterion for
  non-inferiority. Further results on the longer-term safety and
  efficacy of Inflectra from this ongoing 54-week study in CD are
  expected later this year. The study is also examining the treatment
  response and safety profile in patients when switched from Remicade^®(6)
  to Inflectra, and from Inflectra to Remicade^®(6).
• Trumenba (Meningococcal Serogroup B Bivalent Recombinant
  Lipoprotein vaccine) — In March 2017, Pfizer announced that the
  Committee for Medicinal Products for Human Use (CHMP) of the European
  Medicines Agency (EMA) has adopted a positive opinion recommending
  that Trumenba be granted marketing authorization in the European Union
  (EU) for active immunization of individuals 10 years and older to
  prevent invasive meningococcal disease caused by Neisseria
  meningitidis serogroup B. The CHMP’s opinion will now be reviewed
  by the European Commission (EC), which has the authority to approve
  medicines for the EU.
• Xeljanz (tofacitinib)
  • In March 2017, Pfizer announced that the EC approved Xeljanz 5 mg
    twice daily (BID) oral tablets in combination with methotrexate
    (MTX) for the treatment of moderate to severe active rheumatoid
    arthritis (RA) in adult patients who have responded inadequately
    to, or who are intolerant to one or more disease-modifying
    antirheumatic drugs (DMARDs). Xeljanz can be given as monotherapy
    in case of intolerance to MTX or when treatment with MTX is
    inappropriate.
  • In March 2017, Pfizer announced that the Chinese Food and Drug
    Administration approved Xeljanz 5 mg BID in China for the
    treatment of adult patients with moderately to severely active RA
    who have had an inadequate response or intolerance to MTX. Xeljanz
    may be used in combination with MTX or other non-biologic DMARDs.
  • In February 2017, Pfizer announced top-line results from ORAL
    Strategy, a Phase 3B/4 study of Xeljanz 5 mg BID in the treatment
    of moderate to severe RA. ORAL Strategy is the first trial to
    compare a JAK inhibitor as monotherapy or in combination with MTX
    versus adalimumab (Humira^®(7)) plus MTX in MTX
    inadequate responders using ACR50 at Month 6 as the primary
    endpoint. There were three comparisons, which found:
    • Xeljanz 5 mg plus MTX met its primary endpoint in
      demonstrating non-inferiority versus Humira^®(7)
      plus MTX; and
    • Xeljanz 5 mg monotherapy did not meet its primary endpoint of
      non-inferiority versus Humira^®(7) plus MTX or
      versus Xeljanz plus MTX.

      The safety findings were
      consistent with the known adverse events and serious adverse
      events profile for Xeljanz.

• Zavicefta (ceftazidime-avibactam)
  • In April 2017, Pfizer presented positive results of the REPROVE
    study (randomized, multi-center study of ceftazidime-avibactam
    versus meropenem in adults with nosocomial pneumonia including
    ventilator associated pneumonia) that showed that patients
    diagnosed with hospital-acquired pneumonia, treated with
    Zavicefta, a novel combination antibiotic for the treatment of
    certain known or suspected Gram-negative bacterial infections, or
    Meropenem (meropenem for injection), a broad spectrum carbapenem
    antibiotic currently considered the standard of care, experienced
    comparable rates of clinical cure at test-of-cure 21-25 days after
    randomization. Clinical cure was the primary endpoint of the study
    and defined as a complete resolution of all signs and symptoms of
    infection. In addition, patients treated with Zavicefta and
    Meropenem experienced comparable rates of tolerability consistent
    with the known profile of ceftazidime alone. In December 2016,
    Pfizer completed the acquisition of the development and
    commercialization rights to AstraZeneca’s small molecule
    anti-infective business, primarily outside the U.S., including the
    commercialization and development rights to Zavicefta outside
    North America.
  • In March 2017, Pfizer announced that Zavicefta is now available in
    the U.K. and Germany. Pfizer expects to launch Zavicefta in
    additional markets outside the U.S. throughout 2017 and 2018.

Pipeline Developments

A comprehensive update of Pfizer’s development pipeline was published
today and is now available at http://www.pfizer.com/science/drug-product-pipeline.
It includes an overview of Pfizer’s research and a list of compounds in
development with targeted indication and phase of development, as well
as mechanism of action for some candidates in Phase 1 and all candidates
from Phase 2 through registration.

• Ertugliflozin (PF-04971729) — In March 2017, Merck, known as
  MSD outside the U.S. and Canada, and Pfizer, announced that the FDA
  has accepted for review three New Drug Applications (NDAs) for
  medicines containing ertugliflozin, an investigational SGLT2 inhibitor
  in development to help improve glycemic control in adults with type 2
  diabetes: one for monotherapy, one for the fixed-dose combination of
  ertugliflozin and Januvia^®(8) (sitagliptin), and one for
  the fixed-dose combination of ertugliflozin and metformin. The PDUFA
  action date from the FDA is in December 2017 for the three NDAs.
  Additionally, in February 2017, the EMA validated for review three
  Marketing Authorization Applications for ertugliflozin monotherapy and
  the two fixed-dose combination products.
• Inotuzumab Ozogamicin
  • In April 2017, Pfizer announced that the CHMP of the EMA adopted a
    positive opinion recommending approval of Besponsa (inotuzumab
    ozogamicin) in the EU as monotherapy for the treatment of adults
    with relapsed or refractory CD22-positive B-cell precursor
    Philadelphia chromosome negative (Ph-) acute lymphoblastic
    leukemia (ALL) and Philadelphia chromosome positive (Ph+) ALL, who
    have previously failed treatment with at least one tyrosine kinase
    inhibitor. The CHMP’s opinion will now be reviewed by the EC. If
    approved, Besponsa will be the first antibody drug conjugate
    available for patients with this type of leukemia.
  • In February 2017, Pfizer announced that a BLA for inotuzumab
    ozogamicin was accepted for filing and granted Priority Review by
    the FDA. Inotuzumab ozogamicin is being evaluated for the
    treatment of adult patients with relapsed or refractory B-cell
    precursor ALL. The PDUFA goal date for a decision by the FDA is in
    August 2017.
• Lorlatinib (PF-06463922) — Pfizer announced in April 2017 that
  its investigational next-generation anaplastic lymphoma kinase
  (ALK)/ROS1 tyrosine kinase inhibitor, lorlatinib, was granted
  Breakthrough Therapy designation from the FDA for the treatment of
  patients with ALK-positive metastatic non-small cell lung cancer
  (NSCLC), previously treated with one or more ALK inhibitors. The
  Breakthrough Therapy designation is supported by the efficacy and
  safety data of an ongoing Phase 1/2 clinical trial of lorlatinib,
  which includes patients with ALK-positive NSCLC who were previously
  treated with one or more ALK inhibitors.
• PF-06425090 (Clostridium difficile (C. difficile)
  vaccine candidate) — In March 2017, Pfizer initiated a
  randomized, placebo-controlled, observer-blinded Phase 3 study to
  evaluate the efficacy, safety and tolerability of its investigational C.
  difficile vaccine in adults aged 50 and over, who are at risk of
  developing C. difficile infection (CDI). The CLOVER (Clostridium
  difficile Vaccine Efficacy Trial) study will assess whether
  PF-06425090 prevents CDI, and whether it is safe and well tolerated.
  Each patient will receive three doses of PF-06425090 or placebo and be
  followed for up to three years after vaccination. The trial is
  expected to enroll nearly 16,000 patients.

Corporate Developments

• In February 2017, Pfizer announced that it entered into an accelerated
  share repurchase agreement with Citibank N.A. (Citibank) to repurchase
  $5 billion of Pfizer’s common stock. Pursuant to the terms of the
  agreement, on February 6, 2017, Pfizer paid $5 billion to Citibank and
  received an initial delivery of approximately 126 million shares of
  Pfizer common stock from Citibank. At settlement of the agreement,
  which is expected to occur during or prior to the third quarter of
  2017, Citibank may be required to deliver additional shares of common
  stock to Pfizer, or, under certain circumstances, Pfizer may be
  required to deliver shares of its common stock or may elect to make a
  cash payment to Citibank, with the number of shares to be delivered or
  the amount of such payment based on the volume-weighted average price
  of Pfizer’s common stock during the term of the transaction.
• In February 2017, Pfizer completed the sale of HIS to ICU Medical,
  Inc. (ICU Medical) for up to approximately $900 million, composed of
  cash and contingent cash consideration, ICU Medical common stock and
  seller financing.

Please find Pfizer’s press release and associated financial tables,
including reconciliations of certain GAAP reported to non-GAAP adjusted
information, at the following hyperlink:

https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2017/Q1_2017_Earnings_Press_Release.pdf

(Note: If clicking on the above link does not open up a new web page,
you may need to cut and paste the above URL into your browser’s address
bar.)

For additional details, see the associated financial schedules and
product revenue tables attached to the press release located at the
hyperlink referred to above and the attached disclosure notice.

DISCLOSURE NOTICE: Except where otherwise noted, the information
contained in this earnings release and the related attachments is as of
May 2, 2017. We assume no obligation to update any forward-looking
statements contained in this earnings release and the related
attachments as a result of new information or future events or
developments.

This earnings release and the related attachments contain
forward-looking statements about our anticipated future operating and
financial performance, business plans and prospects, in-line products
and product candidates, strategic reviews, capital allocation,
business-development plans, the benefits expected from our acquisitions
of Hospira, Inc. (Hospira), Anacor Pharmaceuticals, Inc. (Anacor),
Medivation, Inc. (Medivation) and AstraZeneca’s small molecule
anti-infectives business and plans relating to share repurchases and
dividends, among other things, that involve substantial risks and
uncertainties. You can identify these statements by the fact that they
use future dates or use words such as “will,” “may,” “could,” “likely,”
“ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,”
“plan,” “believe,” “target,” “forecast,” “goal,” “objective,” “aim” and
other words and terms of similar meaning. Among the factors that could
cause actual results to differ materially from past results and future
plans and projected future results are the following:

• the outcome of research and development activities, including, without
  limitation, the ability to meet anticipated pre-clinical and clinical
  trial commencement and completion dates, regulatory submission and
  approval dates, and launch dates for product candidates, as well as
  the possibility of unfavorable pre-clinical and clinical trial
  results, including unfavorable new clinical data and additional
  analyses of existing clinical data;
• decisions by regulatory authorities regarding whether and when to
  approve our drug applications, which will depend on the assessment by
  such regulatory authorities of the benefit-risk profile suggested by
  the totality of the efficacy and safety information submitted;
  decisions by regulatory authorities regarding labeling, ingredients
  and other matters that could affect the availability or commercial
  potential of our products; and uncertainties regarding our ability to
  address the comments in complete response letters received by us with
  respect to certain of our drug applications to the satisfaction of the
  FDA;
• the speed with which regulatory authorizations, pricing approvals and
  product launches may be achieved;
• the outcome of post-approval clinical trials, which could result in
  the loss of marketing approval for a product or changes in the
  labeling for, and/or increased or new concerns about the safety or
  efficacy of, a product that could affect its availability or
  commercial potential;
• risks associated with interim data, including the risk that final
  results of studies for which interim data have been provided and/or
  additional clinical trials may be different from (including less
  favorable than) the interim data results and may not support further
  clinical development of the applicable product candidate or indication;
• the success of external business-development activities, including the
  ability to satisfy the conditions to closing of announced transactions
  in the anticipated time frame or at all;
• competitive developments, including the impact on our competitive
  position of new product entrants, in-line branded products, generic
  products, private label products, biosimilars and product candidates
  that treat diseases and conditions similar to those treated by our
  in-line drugs and drug candidates;
• the implementation by the FDA and regulatory authorities in certain
  other countries of an abbreviated legal pathway to approve biosimilar
  products, which could subject our biologic products to competition
  from biosimilar products, with attendant competitive pressures, after
  the expiration of any applicable exclusivity period and patent rights;
• risks related to our ability to develop and launch biosimilars,
  including risks associated with « at risk » launches, defined as the
  marketing of a product by Pfizer before the final resolution of
  litigation (including any appeals) brought by a third party alleging
  that such marketing would infringe one or more patents owned or
  controlled by the third party;
• the ability to meet competition from generic, branded and biosimilar
  products after the loss or expiration of patent protection for our
  products or competitor products;
• the ability to successfully market both new and existing products
  domestically and internationally;
• difficulties or delays in manufacturing, including possible legal or
  regulatory actions, such as warning letters, suspension of
  manufacturing, seizure of product, injunctions or voluntary recall of
  a product;
• trade buying patterns;
• the impact of existing and future legislation and regulatory
  provisions on product exclusivity;
• trends toward managed care and healthcare cost containment, and our
  ability to obtain or maintain timely or adequate pricing or formulary
  placement for our products;
• the impact of any significant spending reductions or cost controls
  affecting Medicare, Medicaid or other publicly funded or subsidized
  health programs or changes in the tax treatment of employer-sponsored
  health insurance that may be implemented, and/or any significant
  additional taxes or fees that may be imposed on the pharmaceutical
  industry as part of any broad deficit-reduction effort;
• the impact of any U.S. healthcare reform or legislation, including any
  repeal, substantial modification or invalidation of any or all of the
  provisions of the U.S. Patient Protection and Affordable Care Act, as
  amended by the Health Care and Education Reconciliation Act;
• U.S. federal or state legislation or regulatory action and/or policy
  efforts affecting, among other things, pharmaceutical product pricing,
  reimbursement or access, including under Medicaid, Medicare and other
  publicly funded or subsidized health programs; patient out-of-pocket
  costs for medicines, manufacturer prices and/or price increases that
  could result in new mandatory rebates and discounts or other pricing
  restrictions; the importation of prescription drugs from outside the
  U.S. at prices that are regulated by governments of various foreign
  countries; restrictions on direct-to-consumer advertising; limitations
  on interactions with healthcare professionals; or the use of
  comparative effectiveness methodologies that could be implemented in a
  manner that focuses primarily on the cost differences and minimizes
  the therapeutic differences among pharmaceutical products and
  restricts access to innovative medicines; as well as pricing pressures
  for our products as a result of highly competitive insurance markets;
• legislation or regulatory action in markets outside the U.S. affecting
  pharmaceutical product pricing, reimbursement or access, including, in
  particular, continued government-mandated reductions in prices and
  access restrictions for certain biopharmaceutical products to control
  costs in those markets;
• the exposure of our operations outside the U.S. to possible capital
  and exchange controls, expropriation and other restrictive government
  actions, changes in intellectual property legal protections and
  remedies, as well as political unrest, unstable governments and legal
  systems and inter-governmental disputes;
• contingencies related to actual or alleged environmental contamination;
• claims and concerns that may arise regarding the safety or efficacy of
  in-line products and product candidates;
• any significant breakdown, infiltration or interruption of our
  information technology systems and infrastructure;
• legal defense costs, insurance expenses and settlement costs;
• the risk of an adverse decision or settlement and the adequacy of
  reserves related to legal proceedings, including patent litigation,
  product liability and other product-related litigation, including
  personal injury, consumer, off-label promotion, securities, antitrust
  and breach of contract claims, commercial, environmental, government
  investigations, employment and other legal proceedings, including
  various means for resolving asbestos litigation, as well as tax issues;
• our ability to protect our patents and other intellectual property,
  both domestically and internationally;
• interest rate and foreign currency exchange rate fluctuations,
  including the impact of possible currency devaluations in countries
  experiencing high inflation rates and the volatility following the
  United Kingdom (U.K.) referendum in which voters approved the exit
  from the EU;
• governmental laws and regulations affecting domestic and foreign
  operations, including, without limitation, tax obligations and changes
  affecting the tax treatment by the U.S. of income earned outside the
  U.S. that may result from pending and possible future proposals;
• any significant issues involving our largest wholesale distributors,
  which account for a substantial portion of our revenues;
• the possible impact of the increased presence of counterfeit medicines
  in the pharmaceutical supply chain on our revenues and on patient
  confidence in the integrity of our medicines;
• the end result of any negotiations between the U.K. government and the
  EU regarding the terms of the U.K.’s exit from the EU, which could
  have implications on our research, commercial and general business
  operations in the U.K. and the EU;
• any significant issues that may arise related to the outsourcing of
  certain operational and staff functions to third parties, including
  with regard to quality, timeliness and compliance with applicable
  legal requirements and industry standards;
• any significant issues that may arise related to our joint ventures
  and other third-party business arrangements;
• changes in U.S. generally accepted accounting principles;
• changes in interpretations of existing laws and regulations, or
  changes in laws and regulations, in the U.S. and other countries;
• uncertainties related to general economic, political, business,
  industry, regulatory and market conditions including, without
  limitation, uncertainties related to the impact on us, our customers,
  suppliers and lenders and counterparties to our foreign-exchange and
  interest-rate agreements of challenging global economic conditions and
  recent and possible future changes in global financial markets; and
  the related risk that our allowance for doubtful accounts may not be
  adequate;
• any changes in business, political and economic conditions due to
  actual or threatened terrorist activity in the U.S. and other parts of
  the world, and related U.S. military action overseas;
• growth in costs and expenses;
• changes in our product, segment and geographic mix;
• the impact of purchase accounting adjustments, acquisition-related
  costs, discontinued operations and certain significant items;
• the impact of acquisitions, divestitures, restructurings, internal
  reorganizations, product recalls, withdrawals and other unusual items,
  including our ability to realize the projected benefits of our
  cost-reduction and productivity initiatives and of the internal
  separation of our commercial operations into our current operating
  structure;
• the risk of an impairment charge related to our intangible assets,
  goodwill or equity-method investments;
• risks related to internal control over financial reporting; and
• risks and uncertainties related to our recent acquisitions of Hospira,
  Anacor, Medivation and AstraZeneca’s small molecule anti-infectives
  business, including, among other things, the ability to realize the
  anticipated benefits of those acquisitions, including the possibility
  that expected cost savings related to the acquisition of Hospira and
  accretion related to the acquisitions of Hospira, Anacor and
  Medivation will not be realized or will not be realized within the
  expected time frame; the risk that the businesses will not be
  integrated successfully; disruption from the transactions making it
  more difficult to maintain business and operational relationships;
  significant transaction costs; and unknown liabilities.

We cannot guarantee that any forward-looking statement will be realized.
Achievement of anticipated results is subject to substantial risks,
uncertainties and inaccurate assumptions. Should known or unknown risks
or uncertainties materialize or should underlying assumptions prove
inaccurate, actual results could vary materially from past results and
those anticipated, estimated or projected. Investors should bear this in
mind as they consider forward-looking statements, and are cautioned not
to put undue reliance on forward-looking statements. A further list and
description of risks, uncertainties and other matters can be found in
our Annual Report on Form 10-K for the fiscal year ended December 31,
2016 and in our subsequent reports on Form 10-Q, in each case including
in the sections thereof captioned “Forward-Looking Information and
Factors That May Affect Future Results” and “Item 1A. Risk Factors”, and
in our subsequent reports on Form 8-K.

The operating segment information provided in this earnings release and
the related attachments does not purport to represent the revenues,
costs and income from continuing operations before provision for taxes
on income that each of our operating segments would have recorded had
each segment operated as a standalone company during the periods
presented.

This earnings release may include discussion of certain clinical studies
relating to various in-line products and/or product candidates. These
studies typically are part of a larger body of clinical data relating to
such products or product candidates, and the discussion herein should be
considered in the context of the larger body of data. In addition,
clinical trial data are subject to differing interpretations, and, even
when we view data as sufficient to support the safety and/or
effectiveness of a product candidate or a new indication for an in-line
product, regulatory authorities may not share our views and may require
additional data or may deny approval altogether.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170502005770/en/